Skip to main content
Video

First-Line Ibrutinib Treatment Shows Long-Term Efficacy, High PFS and OS Rates in CLL


December 06, 2020

ohn Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian HospitalBased on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based treatment resulted in sustained efficacy with high progression-free survival and overall survival rates in CLL patients with TP53 aberrations—a population with historically poor outcomes.

 

Reference:

Allen JN,  Shanafelt T, Wiestner A, et al. Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials (Abstract 2219) https://ash.confex.com/ash/2020/webprogram/Paper134431.html. December 6, 2020.

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
12 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top